Dr. Kevan E. Clemens Ph.D. serves as Independent Director of the Company. He has a long and distinguished career in the pharmaceutical industry, highlighted by 25 years at Labratorios Syntex SA and Hoffman-La Roche in a number of development, sales and marketing positions. As Executive Vice President, Business Director at Roche, he was responsible for the blockbuster Global Oncology franchise, including its strategic plans, development and marketing. Prior to that, he was Vice President, Global Head of Specialty Care, Vice President, Global Head of Project Management and Vice President, Global Head of Clinical Operations for North and South America. Dr. Clemens served on the board of directors of Chelsea Therapeutics International from 2004 until its acquisition by H. Lundbeck A/S in June 2014. He also served on the board of directors of Kosan Biosciences from 2005 to 2008. Dr. Clemens obtained his Ph.D. in Chemistry from the University College London.
As the Independent Director of MEI Pharma Inc, the total compensation of Kevan Clemens at MEI Pharma Inc is $161,444. There are 11 executives at MEI Pharma Inc getting paid more, with Daniel Gold having the highest compensation of $1,854,410.
Kevan Clemens is 75, he's been the Independent Director of MEI Pharma Inc since 2014. There are no older and 15 younger executives at MEI Pharma Inc.
Kevan's mailing address filed with the SEC is C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L..., and Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
MEI Pharma Inc executives and other stock owners filed with the SEC include: